Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCHO Pharma Inc. 〉Homogeneous antibody drugs (CHO-H01, H02, H03)

Homogeneous antibody drugs (CHO-H01, H02, H03)

Homogeneous antibody drugs (CHO-H01, H02, H03)

The first product, Homogeneous Antibody Drug for Cancer, has entered the GMP production stage and the IND application will be submitted by the end of 2016.

Request for Collaboration
Overview
A unique glycan structure was identified for monoclonal antibodies with improved activity. With the proprietary technology developed by CHO Pharma, the Fc-glycan structure of therapeutic antibodies can be engineered to a homogeneous glycoform, which displayed enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC), in vivo anti-tumor activities, and potential anti-inflammatory properties.

Using this platform technology, we were able to engineer the glycans on the therapeutic antibodies for cancers and autoimmune diseases, including Rituxan (for non-Hodgkin's lymphoma), Herceptin (for HER2 Positive Metastatic Breast Cancer and gastric cancer) and Humira (for Rheumatoid Arthritis).

Our core technology - Homogeneous Antibody Drug Technologies - is expected to drive the development of breakthrough glycan-based pharmaceuticals. The first product, Homogeneous Antibody Drug for Cancer, has entered the GMP production stage and the IND application will be submitted by the end of 2016. This approach produces drugs with high therapeutic effectiveness, have better efficacy with reduced side effects or non-immune responses and more defined CMC.
Patent Portfolio
Collaboration Options
Global pharmaceutical revenues had reached over one trillion US dollars in 2014, comprising 26.1 billion in the North America. In 2008, BioMedTracker indicates that FDA approved 20 new molecular entities (NMEs) with an approval rate of 50%. That rate grown drastically since then and even rose to 88% in 2015, indicating that we're living in a golden age of drug approvals. Taking example of the 50 new drugs approved in 2014, 20 of which were large molecule drugs. Furthermore, three of the five large molecule drugs approved in 2015 by FDA were antibody drugs (Praluent/Sanofi, Repatha/Amgen, Nucala/GSK).  Among these, the global glycoengineered antibodies market is expected to approach 1.7 billion US dollars in 2018, and expand to 4.5 billion US dollars in 2023.
 
People who like this also like
  • Multi-day Transdermal Drug Delivery (MTDD)Multi-day Transdermal Drug Delivery (MTDD)
  • Platform_Polymeric MicellePlatform_Polymeric Micelle
  • PeptidePeptide
  • Preimplantation Genetic DiagnosisPreimplantation Genetic Diagnosis
  • Six Genomic Technology PlatformsSix Genomic Technology Platforms
  • Lead optimizationLead optimization
  • Carrier screening for fragile X syndromeCarrier screening for fragile X syndrome
  • Small Molecule DrugsSmall Molecule Drugs
  • Lesion Detecting Method and Lesion Detecting Apparatus for Breast Image in Rotating MannerLesion Detecting Method and Lesion Detecting Apparatus for Breast Image in Rotating Manner
  • TLC590TLC590